[{"abstract": "Recent deals show that normally sober-minded business executives seem to have thrown over sound decision-making for flights of fancy.", "web_url": "https://www.nytimes.com/2015/11/25/business/dealbook/telltale-signs-that-deal-makers-swallowed-the-silly-pills.html", "snippet": "Recent deals show that normally sober-minded business executives seem to have thrown over sound decision-making for flights of fancy.", "lead_paragraph": "Even in these grim times, deal makers have descended into silliness.", "print_section": "B", "print_page": "5", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/25/business/25DEALPROF/25DEALPROF-articleLarge.jpg", "height": 600, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/11/25/business/25DEALPROF/25DEALPROF-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 600}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/25/business/25DEALPROF/25DEALPROF-jumbo.jpg", "height": 1024, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/25/business/25DEALPROF/25DEALPROF-superJumbo.jpg", "height": 1196, "width": 1196, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/25/business/25DEALPROF/25DEALPROF-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/11/25/business/25DEALPROF/25DEALPROF-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/25/business/25DEALPROF/25DEALPROF-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer-Allergan Merger Is Latest Sign of Deal Makers\u2019 Silly Pills", "kicker": null, "content_kicker": null, "print_headline": "Telltale Signs That Deal Makers Swallowed the Silly Pills ", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Corporate Taxes", "rank": 1, "major": "N"}, {"name": "organizations", "value": "ALLERGAN INC", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Mylan Inc", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Perrigo Company", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 5, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 6, "major": "N"}, {"name": "organizations", "value": "Pershing Square Capital Management", "rank": 7, "major": "N"}, {"name": "persons", "value": "Ackman, William A", "rank": 8, "major": "N"}, {"name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "rank": 9, "major": "N"}, {"name": "organizations", "value": "Herbalife Ltd", "rank": 10, "major": "N"}, {"name": "subject", "value": "Taxation", "rank": 11, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 12, "major": "N"}, {"name": "persons", "value": "Coury, Robert J", "rank": 13, "major": "N"}], "pub_date": "2015-11-25T00:54:37+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Steven Davidoff Solomon", "person": [{"firstname": "Steven", "middlename": "Davidoff", "lastname": "Solomon", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/3ad0ef27-5f51-5570-8649-56dddee4f1b5", "word_count": 1201, "uri": "nyt://article/3ad0ef27-5f51-5570-8649-56dddee4f1b5"}, {"abstract": "An offshore tax address means there\u2019s no reason to keep over $60 billion of cash on its balance sheet. That\u2019s a lot of financial firepower to buy back shares and fuel more acquisitions.", "web_url": "https://www.nytimes.com/2015/11/26/business/dealbook/how-allergan-deal-will-rebuild-pfizers-war-chest.html", "snippet": "An offshore tax address means there\u2019s no reason to keep over $60 billion of cash on its balance sheet. That\u2019s a lot of financial firepower to buy back shares and fuel more acquisitions.", "lead_paragraph": "It sounds counterintuitive, but Pfizer\u2019s $152 billion takeover of Allergan will rebuild the acquisitive drug giant\u2019s war chest to do even more deals. Because it was structured as a merger, allowing it to flip its tax liabilities overseas, most of what Pfizer is paying comes in the form of stock. That means the pharma mega-beast will be flush with cash and eager to put it to work.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-articleLarge.jpg", "height": 395, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 395}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-jumbo.jpg", "height": 674, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-superJumbo.jpg", "height": 1349, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "How Allergan Deal Will Rebuild Pfizer\u2019s War Chest", "kicker": "Breakingviews", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "subject", "value": "Federal Taxes (US)", "rank": 2, "major": "N"}, {"name": "subject", "value": "Taxation", "rank": 3, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 4, "major": "N"}, {"name": "organizations", "value": "ALLERGAN INC", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 6, "major": "N"}, {"name": "persons", "value": "Read, Ian C", "rank": 7, "major": "N"}], "pub_date": "2015-11-25T18:21:43+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Robert Cyran", "person": [{"firstname": "Robert", "middlename": null, "lastname": "Cyran", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/c7d78ab7-327e-5b0f-81c7-dad490a47c89", "word_count": 369, "uri": "nyt://article/c7d78ab7-327e-5b0f-81c7-dad490a47c89"}, {"abstract": "The Pfizer-Allergan merger has been criticized because of a planned headquarters move to Ireland, but such strategies are not necessary to avoid taxes.", "web_url": "https://www.nytimes.com/2015/11/29/business/dealbook/pfizer-didnt-need-an-inversion-to-avoid-paying-us-taxes.html", "snippet": "The Pfizer-Allergan merger has been criticized because of a planned headquarters move to Ireland, but such strategies are not necessary to avoid taxes.", "lead_paragraph": "Pfizer\u2019s declaration that it intends to merge with Allergan and cut taxes by moving its tax home to Dublin from New York City has set off something of a furor.", "print_section": "BU", "print_page": "3", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/29/business/29-STRA/29-STRA-articleLarge-v2.jpg", "height": 473, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2015/11/29/business/29-STRA/29-STRA-articleLarge-v2.jpg", "xlargewidth": 600, "xlargeheight": 473}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/29/business/29-STRA/29-STRA-jumbo-v2.jpg", "height": 808, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/29/business/29-STRA/29-STRA-superJumbo-v2.jpg", "height": 1615, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/29/business/29-STRA/29-STRA-thumbStandard-v2.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2015/11/29/business/29-STRA/29-STRA-thumbStandard-v2.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2015/11/29/business/29-STRA/29-STRA-thumbLarge-v2.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer Didn\u2019t Need an Inversion to Avoid Paying U.S. Taxes", "kicker": "Strategies", "content_kicker": null, "print_headline": "The Benefits of Keeping Earnings in Exile", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Corporate Taxes", "rank": 1, "major": "N"}, {"name": "subject", "value": "Tax Shelters", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 4, "major": "N"}, {"name": "organizations", "value": "ALLERGAN INC", "rank": 5, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 6, "major": "N"}], "pub_date": "2015-11-25T19:04:50+0000", "document_type": "article", "news_desk": "SundayBusiness", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Jeff Sommer", "person": [{"firstname": "Jeff", "middlename": null, "lastname": "Sommer", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/83a0c8a3-2469-57ec-8a11-409f77e8169f", "word_count": 1127, "uri": "nyt://article/83a0c8a3-2469-57ec-8a11-409f77e8169f"}]